Trial Profile

Phase 2 study of CMX-2043 for the treatment of Traumatic Brain Injury

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 31 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CMX 2043 (Primary)
Indications Traumatic brain injuries
Focus Therapeutic Use

Most Recent Events

31 Aug 2023 New trial record
30 Aug 2023 According to a Ischemix media release, the company expects to complete all of the work required for this trial by the end of 2023, and plans to request a pre-IND meeting with FDA for early Q1 2024.
25 Aug 2023 According to a Ischemix media release, the company is in the process of designing the protocol for a Phase 2 trial and will be Phase 2-ready by the first quarter of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com